Immunotherapies and Targeted Therapies: New Frontiers in Melanoma Treatment
Immunotherapies and Targeted Therapies: New Frontiers in Melanoma Treatment
-
DOI: 10.22533/at.ed.12523041222
-
Palavras-chave: melanoma; terapias emergentes; imunoterapia; terapia-alvo; inibidores de checkpoint; células T; inibidores de BRAF; inibidores de MEK.
-
Keywords: melanoma; emerging therapies; immunotherapy; targeted therapy; checkpoint inhibitors; T cells; BRAF inhibitors; MEK inhibitors.
-
Abstract: Melanoma is a type of skin cancer with high lethality, particularly in its more advanced stages. This study reviewed recent literature to understand the emerging therapies in the treatment of melanoma. A total of 150 studies were analyzed, with a clear predominance of investigations focused on immunotherapies and targeted therapies. The reviewed immunotherapies were mainly T cell therapies and checkpoint inhibitor therapies, while the targeted therapies focused on BRAF and MEK inhibitors. All these therapies showed promise, but also present considerable challenges, such as therapy resistance and toxicity. This study underscores the need for continued research to overcome these challenges and customize treatments for melanoma patients.
- Francyane Peixoto Ramos de Abreu
- Germana Furtado da Graça Cezar
- Valentina Morelli Barbosa
- Luana Gomes Dias Pimentel
- Guilherme Machado Carvalheira
- Paulo Roberto Hernandes Júnior
- Juliana de Souza Rosa
- Nathan Noronha Fidelis Hernandes
- Rossy Moreira Bastos Junior
- Paula Pitta de Resende Côrtes
